^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    21h
    Heterogeneity study on MiRNA expression in islet cells of rat pancreatic head and tail. (PubMed, BMC Med Genomics)
    Our findings provide novel insights into the heterogeneity of miRNA expression in the pancreas and the molecular mechanisms underlying pancreatic cancer, offering potential targets for future diagnostic and therapeutic strategies.
    Preclinical • Journal
    |
    MIR124-3 (MicroRNA 124-3)
    21h
    Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression. (PubMed, Nat Commun)
    Importantly, inactivation of the necroptosis executioner MLKL reverses pre-tumoral inflammation, decreases metastasis as well as neuronal-like reprogramming. Taken together, our findings suggest that pre-tumoral inflammatory cell death contributes to neuronal progenitor mimicry, immunosuppression and increased metastasis in SCLC.
    Journal
    |
    CASP8 (Caspase 8)
    21h
    Germline alterations in patients with lung cancer. (PubMed, Ann Oncol)
    Similar distribution of P/LP potential germline alterations in lung cancer subtypes from distinct populations by smoking status suggests increased next-generation germline sequencing may improve risk assessment.
    Journal • BRCA Biomarker
    |
    EGFR (Epidermal growth factor receptor) • BRCA2 (Breast cancer 2, early onset) • CHEK2 (Checkpoint kinase 2) • MUTYH (MutY homolog)
    |
    EGFR wild-type
    |
    Tempus xT Assay
    1d
    Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial (clinicaltrials.gov)
    P1/2, N=63, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • etoposide IV
    1d
    Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. (PubMed, Clin Transl Med)
    CAFs-derived exosomal miR-3126-5p enhanced glycolysis of NSCLC cells via targeting KLF13. KLF13 led to transcriptional inhibition of SH2B1 in NSCLC cells. SH2B1 interplayed with IRS1 to facilitate glycolysis of NSCLC cells. IRS1 promoted glycolysis of NSCLC cells via the activation of PI3K/AKT pathway.
    Journal
    |
    IRS1 (Insulin Receptor Substrate 1) • MIR126 (MicroRNA 126)
    2d
    A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P2 trial
    3d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    3d
    A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice (clinicaltrials.gov)
    P=N/A, N=700, Recruiting, Hoffmann-La Roche
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)
    3d
    Tarlatamab for small-cell lung cancer. (PubMed, Expert Opin Biol Ther)
    Most data come from SCLC; in the other two diseases, tarlatamab is in early clinical development. Tarlatamab is an effective therapy mainly in relapsed/progressed SCLC, and its assessment in limited SCLC alone or combined with other therapies is supported by the existing data.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Imdelltra (tarlatamab-dlle)
    4d
    Telomere length and oxidative stress in small-cell lung cancer: commentary on prognostic value. (PubMed, Biochem Med (Zagreb))
    It emphasizes the importance of integrating telomere biology and oxidative stress assessment in prognostic modeling. The discussion also considers the modifying effects of lifestyle, treatment regimens, and genetic background, advocating for research that combines clinical, biochemical, and molecular data to enhance prognostication in SCLC.
    Review • Journal
    |
    PON1 (Paraoxonase 1)
    4d
    A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=208, Recruiting, IDEAYA Biosciences | N=90 --> 208
    Enrollment change
    |
    Imfinzi (durvalumab) • IDE161
    4d
    BL-B01D1-LUNG-101: Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors (clinicaltrials.gov)
    P1, N=470, Recruiting, SystImmune Inc. | N=260 --> 470 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial primary completion date
    |
    izalontamab brengitecan (BL-B01D1)